LobbyingHologic lobbying by quarter
Hologic's latest lobbying report covers Q2 2026, at $420K. The four quarters Q4 2025–Q3 2026 total $1.3M. Its first report covers Q3 2015; the issues it reports most are Health Issues and Trade (Domestic & Foreign).
Hologic
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1.3M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2015
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2015 | $40K | 1 |
| Q4 2015 | $0 | 0 |
| Q1 2016 | $0 | 0 |
| Q2 2016 | $0 | 0 |
| Q3 2016 | $0 | 0 |
| Q4 2016 | $0 | 0 |
| Q1 2017 | $0 | 0 |
| Q2 2017 | $0 | 0 |
| Q3 2017 | $0 | 0 |
| Q4 2017 | $0 | 0 |
| Q1 2018 | $0 | 0 |
| Q2 2018 | $0 | 0 |
| Q3 2018 | $0 | 0 |
| Q4 2018 | $0 | 0 |
| Q1 2019 | $0 | 0 |
| Q2 2019 | $0 | 0 |
| Q3 2019 | $0 | 0 |
| Q4 2019 | $0 | 0 |
| Q1 2020 | $0 | 0 |
| Q2 2020 | $0 | 0 |
| Q3 2020 | $0 | 0 |
| Q4 2020 | $0 | 0 |
| Q1 2021 | $0 | 0 |
| Q2 2021 | $0 | 0 |
| Q3 2021 | $0 | 0 |
| Q4 2021 | $0 | 0 |
| Q1 2022 | $0 | 0 |
| Q2 2022 | $0 | 0 |
| Q3 2022 | $0 | 0 |
| Q4 2022 | $410K | 4 |
| Q1 2023 | $460K | 3 |
| Q2 2023 | $590K | 3 |
| Q3 2023 | $390K | 3 |
| Q4 2023 | $340K | 3 |
| Q1 2024 | $420K | 3 |
| Q2 2024 | $500K | 3 |
| Q3 2024 | $380K | 2 |
| Q4 2024 | $370K | 2 |
| Q1 2025 | $510K | 2 |
| Q2 2025 | $530K | 2 |
| Q3 2025 | $390K | 2 |
| Q4 2025 | $380K | 2 |
| Q1 2026 | $530K | 2 |
| Q2 2026 | $420K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$5.4M · 31 reports
- Trade$408.3K · 5 reports
- Manufacturing$285K · 4 reports
- Medicare and Medicaid$260.8K · 5 reports
- Budget and appropriations$250.8K · 3 reports
- Medical research and clinical labs$13.3K · 1 reports
- Defense$10K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES33 reports
- SENATE33 reports
- Health & Human Services, Dept of (HHS)23 reports
- Centers For Medicare and Medicaid Services (CMS)16 reports
- Food & Drug Administration (FDA)16 reports
- Commerce, Dept of (DOC)11 reports
- Labor, Dept of (DOL)7 reports
- Health Resources & Services Administration (HRSA)3 reports
- Executive Office of the President (EOP)1 reports
- State, Dept of (DOS)1 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseHologic | $4.3M | 15 quarters |
| Alston & Bird | $2.4M | 16 quarters |
| Capitol Counsel | $20K | 1 quarters |
| Arnold & Porter Kaye Scholer | $10K | 7 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| LAURA FRIEDEL | Senate Appropriations Committee - Staff Director, Subcommittee on Labor, Health and Human Services, Education and Related Agencies; Legislative Director/Legislative Assistant, Senator Richard Shelby; Legislative Assistant, Senator Zell Miller. | Q4 2025 |
| ALEXANDER GRAF | Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow. | Q2 2025 |
| PHYLICIA WOODS LISIAK | Counsel-Senate Homeland Security and Governmental Affairs Committee, Health Counsel-Senate Special Committee on Aging, Sen. Claire McCaskill. Legislative Assistant, Legislative Correspondent, Rep. Russ Carnahan. | Q1 2025 |
| EVAN COLLIER | Legislative Correspondent and Staff Assistant, Rep. Jeff Denham. | Q3 2024 |
| JOSEPH BODDICKER | Tax Counsel, Senate Finance Cmte; Tax & Trade Counsel, Sen. Thune; Staff Dir., Senate Finance Subcmte on Tax; Tax Counsel/LA, Sen. Heller; Staff Dir., Senate Finance Subcmte on Energy; Finance Counsel, Sen. Gardner; LA/LC/SA, Sen. Thune. | Q3 2024 |
| CAROLINE DOXSEE | Legislative Assistant, Rep. Marcus Molinaro. | Q1 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Alston & Bird | $140K |
| 07/14for Q2 | In-house | $280K |
| 04/20for Q1 | Alston & Bird | $140K |
| 04/16for Q1 | In-house | $390K |
| 03/03for Q1 2025 | Alston & Bird | $160K |
| 01/20for Q4 2025 | Alston & Bird | $140K |
| 01/20for Q4 2025 | In-house | $240K |
| 25/10/20for Q3 2025 | Alston & Bird | $160K |
| 25/10/17for Q3 2025 | In-house | $230K |
| 25/10/16for Q3 2015 | Alston & Bird | $40K |
| 25/07/21for Q2 2025 | In-house | $370K |
| 25/07/21for Q2 2025 | Alston & Bird | $160K |
| 25/05/05for Q4 2024 | In-house | $210K |
| 25/04/21for Q1 2025 | Alston & Bird | $160K |
| 25/04/21for Q1 2025 | In-house | $350K |
| 25/01/21for Q4 2024 | Alston & Bird | $160K |
| 25/01/21for Q4 2024 | In-house | $190K |
| 24/10/21for Q3 2024 | Alston & Bird | $160K |
| 24/10/16for Q3 2024 | In-house | $220K |
| 24/07/22for Q2 2024 | Alston & Bird | $160K |